SobotaJ.T.Erythropoietin treatment of end-stage renal disease: North American and Japanese experience. In: GarnickM.B., ed. Erythropoietin in clinical applications.New York: Dekker, 1990; 183–219.
2.
MacDougallI.C., RobertsD.E., ColesG.A., WilliamsJ.D.Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).Clin Pharmacokinet1991; 20: 99–113.
KromerG., SolfA., EhmerB., KaufmannB., QuelhorstE.Single dose pharmacokinetics of recombinant human erythropoietin comparing intravenous, subcutaneous and intraperitoneal administration in IPD patients (Abstract).Kidney Int1990; 37: 331.
5.
EvansJ.H.C., BrocklebankJ.T., BowmerC.J., NgP.C.Pharmacokinetics of recombinant human erythropoietin in children with renal failure.Nephrol Dial Transplant1991; 6: 709–14.
6.
MacDougallI.C., JonesJ.M., RobinsonM.I., MilesJ.B., ColesG.A., WilliamsJ.D.Subcutaneous erithropoietin therapy: comparison of three different sites of injection.Contrib Nephrol1991; 88: 152–8.
7.
HalstensonC.E., MacresM., KatzS.A.Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.Clin Pharmacol Ther1991; 50: 702–12.
8.
BommerJ., BarthH.P., ZeierM.Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients.Contrib Nephrol1991; 88: 136–43.
9.
ZehnderC., BlumbergA.Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutanous administration.Nephron1991; 57: 485–6.
10.
BesarabA., BesarabF.M., MillerD.Effects of dialysis factors and route of administrations on response of hemodialysis patients to recombinant human erythropoietin.ASAIO Trans1991; 37: M182.
11.
LuiS.F., LawC.B., TingS.M., LaiK.N.Once weekly versus twice weekly subcutaneous administration of recombinant human erithropoietin in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol1991; 36: 246–51.
12.
GranollerasC., BrangerB., ShaldonS.Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration.Contrib Nephrol1991; 88: 144–8.
13.
BesarabA., GolperT.A.Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.ASAIO Trans1991; 37: M395–6.
14.
StevensJ.M., AuerJ., StrongC.A.Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant1991; 6: 487–94.
15.
BaranyP., TranaeusA., BergstromJ.Long-term effects of recombinant human erythropoietin in patients treated with continuous peritoneal dialysis: safety aspects.Contr Nephrol1991; 88: 167–79.
16.
BommerJ., WeinreichT., RitzE., ZeierM., BommerG.Efficacy of subcutaneous or intravenous recombinant human erythropoietin therapy in dialysis patients (Abstract).Nephrol Dial Transplant1989; 4: 471.
17.
FrenkenL.A.M., van LierH.J.J., GerlagP.G.G., den HartogM., KoeneR.A.P.Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis.Br Med J1991; 303: 288.
18.
LuiS.F., LeungC.B., LiP.K.T., LaiK.N.Pain after subcutaneous injection of erythropoietin.Br Med J1991; 303: 856 (letter).
19.
GranollerasC., LeskopfW., ShaldonS., FourcadeJ.Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double blind crossover study.Clin Nephrol1991; 36: 294–8.
20.
VeysN., VanholderR., LameireN.Pain at the injection site of subcutaneously administered erythropoietin (EPO) in maintenance haemodialysis patients: a comparison of two brands of EPO.Am J Nephrol1992; 12: 68–72.
